MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market Share

Statistics for the 2023 & 2024 MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors market share, created by Mordor Intelligence™ Industry Reports. MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Inhibitors Research MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market Market Share

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Industry

The SGLT 2 inhibitors market is highly consolidated, with a few significant manufacturers having a Middle East and Africa market presence. The joint ventures between players in the recent past have helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim manufacture Jardiance, a popular SGLT 2 class drug.

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market Leaders

  1. Astrazeneca

  2. Bristol-Myers Squibb

  3. Eli Lilly

  4. Janssen

  5. Astellas

*Disclaimer: Major Players sorted in no particular order

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Market Concentration

MEA Sodium-dependent Glucose Co-transporter 2 Inhibitors Report Snapshots

MIDDLE EAST & AFRICA SODIUM-DEPENDENT GLUCOSE CO-TRANSPORTER 2 (SGLT 2) INHIBITORS MARKET Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)